ImmunityBio, Inc. (IBRX) Stock: Price, Forecast & Analyst Target
ImmunityBio, Inc. (IBRX) — MoonshotScore 12/100 (Weak band), calculated Nov 18, 2026. Price $6.57 (-1.94%), as of the Nov 19, 2026 trading session; market cap $6.99B.
Educational signal · not a buy or sell recommendation · How to read this
ImmunityBio, Inc. · IBRX · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered): Nasdaq-listed ImmunityBio develops immunotherapies and cell therapies for cancers and infectious diseases, while reported revenue now comes overwhelmingly from product sales. That makes it more than a pipeline biotechnology story, but not yet a self-funding commercial company. The case depends on whether rising product revenue can overtake research, selling, and financing demands before cash consumption forces further balance-sheet action.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · ImmunityBio (IBRX)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Only growth holds up — quality and the balance sheet are near the sector floor; far more to fix here than to build on, and it’s expensive on top. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Strained; Valuation: Full; Growth Durability: Growing; Momentum: Surging.
- EPS beat 3 of the last 8 reports
- Altman Z -13.30 · Piotroski F 3
- ROE 124.6% · current ratio 4.27 · earnings yield -17.5% · free-cash-flow yield -4.7%
Holding back: weak fundamentals
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 13 | Weak | |
| 13 | Weak | |
| 13 | Weak | |
| 13 | Weak | |
| 12 | Weak | |
| 12 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $6.57 | |
| Change on the day | -1.94% | |
| 52-week range | $1.95–$12.43 | |
| Market capitalisation | $6.99B | — |
| Shares traded on the day | 10.88M | |
| Beta (volatility vs the S&P 500) | 0.13 |
Why ImmunityBio scores 12
Share price, last 12 months +211.7%
$2.14 $6.67
How the stock reacts to earnings
EPS beat in 4 of the last 12 reports (2024–2026); the stock still fell the next session after 3 of those beats. Average first-session move: 11.6% either way.
- +14.5%Mar ’24
- +2.5%May ’24
- -17.2%Aug ’24
- -11.4%Nov ’24
- -8.2%Mar ’25
- +21.3%May ’25
- -1.2%Aug ’25
- -4.9%Nov ’25
- +32.8%Feb ’26
- +1.6%May ’26
- +1.4%Aug ’26
- -21.9%Nov ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| Miss | Miss | -21.9% | — | |
| Miss | Beat | +1.4% | +6.3% | |
| Miss | Beat | +1.6% | -2.7% | |
| Beat | In line | +32.8% | +20.0% | |
| Beat | Miss | -4.9% | -5.3% | |
| In line | Miss | -1.2% | +2.5% | |
| Miss | In line | +21.3% | +35.3% | |
| Beat | Miss | -8.2% | -11.6% | |
| Beat | Miss | -11.4% | -1.8% | |
| Miss | Miss | -17.2% | -11.9% | |
| Miss | Beat | +2.5% | -2.1% | |
| Miss | Beat | +14.5% | -2.1% |
The market has been forgiving after misses, which says investors are looking past the quarter to the longer story.
Our track record on this stock
Since the score went from 9 to 12 while the share price moved -13.3% through .
The score has stayed in the Weak band across the stretch we have recorded; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 100% of 5 rate it a buy; the average target sits +128.3% from the price of $6.57.
- Last 90 days: 2 rating actions, every one a reaffirmation.
- Our signals: Weak band; strongest pillar Momentum (82), weakest Business Quality (23).
The crowd is more enthusiastic than our signals. Our Business Quality reading is the main reason.
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for ImmunityBio (IBRX): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Five of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Griffin-style lens, Simons-style lens, Englander-style lens and Moon AI lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is ImmunityBio (IBRX), and what does it report?
Short answer · as of
ImmunityBio combines antibody-cytokine fusion proteins, immune-modulating agents, vaccines, natural killer cell therapies, and adaptive T-cell approaches across cancer and infectious-disease programs.
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
Its economics therefore span commercial product sales and the continuing cost of advancing a broad therapeutic platform.
Reported revenue is almost entirely product revenue, with other product-and-service activity contributing little. The income statement is measuring an emerging commercial business inside a research-heavy biotechnology company, not merely collaboration payments from an otherwise pre-revenue pipeline.
What do the latest results show for ImmunityBio (IBRX)?
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
Revenue has increased throughout the reported quarterly series, and gross profit has remained close to revenue as sales scaled. In the latest period, revenue exceeded the prevailing estimate and the operating loss narrowed, even though research and selling costs together remained well above gross profit.
The commercial progress did not translate into proportionate bottom-line improvement. Net loss and per-share loss were far worse than expected, while operating cash use accelerated sharply; the large separation between operating loss and net loss shows that the headline result was not driven by the core operating deficit alone.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2026 | $49M | -$185M | -$0.17 (diluted) |
| Jun 2026 | $51M | -$230M | -$0.22 (diluted) |
| Mar 2026 | $44M | -$633M | -$0.62 (diluted) |
| Dec 2025 | $38M | -$62M | -$0.06 (diluted) |
What are the financial strengths and risks for ImmunityBio (IBRX)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
High gross margins and rising product sales are the clearest financial strengths. Cash and short-term investments also support strong near-term liquidity ratios, and the cash balance has improved substantially from its earlier low.
Those strengths sit against debt that materially exceeds cash, persistent operating losses, and a recent acceleration in cash consumption. The estimated runway is limited at the current spending rate, while distress and quality screens remain weak; a stalled product ramp combined with continued research spending would bring financing pressure forward.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -13.30 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at ImmunityBio (IBRX)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $200.87M · EPS -1.13 · 2 analysts.
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
Product revenue, operating loss, and operating cash use belong on the same scorecard at the scheduled earnings update. A stronger commercial transition would pair continued sales growth with a narrowing operating deficit and slower cash depletion; another wide gap between operating and net loss would keep attention on financial burdens outside core operations.
Liquidity should be tracked against debt and the current burn rate, not viewed in isolation. Longer-range analyst estimates assume a steep revenue expansion, yet their range is broad and the contributing analyst base thins materially, making actual product-sales progression more informative than the distant averages.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does ImmunityBio compare with its peers?
Short answer
ImmunityBio's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
ImmunityBio differs from pre-revenue biotechnology peers because product sales are already material and carry high reported gross margins. It also differs from mature specialty pharmaceutical businesses because research spending, operating losses, cash burn, and leverage still dominate the financial profile.
That hybrid structure makes commercial execution unusually important: product adoption must fund a platform spanning natural killer cells, adaptive T cells, vaccines, and engineered immune therapies. Pipeline breadth may create additional opportunities, but it also sustains costs while the marketed-product base is still developing.
| Company | Price | Market value | Score |
|---|---|---|---|
| $95.05 Nov 18, 2026 | $7.47B | 98 5-pillar Nov 18, 2026 | |
| $315.34 Nov 18, 2026 | $9.34B | 96 5-pillar Nov 18, 2026 | |
| $93.04 Nov 19, 2026 | $10.6B | 95 5-pillar Nov 18, 2026 | |
| $67.79 Nov 18, 2026 | $7.42B | 91 5-pillar Nov 18, 2026 | |
| $66.12 Nov 18, 2026 | $9.99B | 90 5-pillar Nov 18, 2026 | |
| $127.16 Nov 18, 2026 | $8.30B | 88 5-pillar Nov 18, 2026 | |
| $41.37 Nov 18, 2026 | $4.53B | 84 5-pillar Nov 18, 2026 | |
| $19.50 Nov 18, 2026 | $5.59B | 83 5-pillar Nov 18, 2026 | |
| $298.71 Nov 18, 2026 | $5.98B | 71 5-pillar Nov 18, 2026 | |
| $95.74 Nov 18, 2026 | $6.49B | 67 5-pillar Nov 18, 2026 | |
| $13.76 Nov 18, 2026 | $4.83B | 67 5-pillar Nov 18, 2026 | |
| $124.86 Nov 18, 2026 | $5.27B | 66 5-pillar Nov 18, 2026 | |
| ImmunityBio (IBRX) — this page | $6.57 | $6.99B | 12 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $14.00 – $16.00
- Consensus target
- $15.00
- Median target
- $15.00
- Revenue estimate
- $200.87M
- EPS estimate
- $-1.13
Consensus record · Captured .
Measured against a quoted price of $6.57 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 5, 2026
- Transactions
- 32
- Identified insiders
- 7
- Purchases
- 0
- Sales
- 8
- Other transactions
- 24
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held IBRX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported IBRX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about ImmunityBio (IBRX)?
- ImmunityBio Named No. 2 Fastest-Growing Technology Company in North America on the 2026 Deloitte Technology Fast 500™
- ImmunityBio (IBRX) Could Be 53% Undervalued As Anktiva Trial Results Lift FDA Hopes
- ImmunityBio, Inc. Named to Deloitte 2026 North America Technology Fast 500
- IBRX CEO Reveals Fresh Anktiva Data After Bladder Cancer Trial Win — Says FDA Filing Is Just Weeks Away
ImmunityBio Healthcare Stock: Key Questions Answered
Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered); the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How do ImmunityBio’s natural killer cell and adaptive T-cell platforms fit its business?
They form part of a wider immunotherapy suite that also includes antibody-cytokine fusion proteins, immune-modulating agents, and vaccine technologies. The platform targets cancers and infectious diseases, so commercial product sales coexist with substantial continuing research activity.
Why does rising product revenue not yet make ImmunityBio self-funding?
Gross profit has grown with product sales, but research and selling costs remain larger than gross profit and operations continue to consume cash. Commercial growth therefore has not yet absorbed the cost of the wider platform.
What makes ImmunityBio’s latest net loss different from its operating loss?
The operating deficit narrowed while the net loss remained far larger, creating an unusually wide separation between core operating performance and the bottom line. The per-share result also missed expectations despite revenue exceeding the estimate.
Can ImmunityBio fund its immunotherapy rollout from current cash?
Current cash and short-term investments support near-term liquidity, but they remain below total debt and imply limited runway at the prevailing burn rate. Continued product growth, slower cash use, or additional financing would be needed to extend that position.
What is the IBRX stock price today?
The last price recorded for ImmunityBio, Inc. (IBRX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the IBRX price target?
The analyst consensus price target for ImmunityBio, Inc. (IBRX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 16 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
